NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

NewAmsterdam Pharma (Nasdaq: NAMS) announced inducement grants of options covering 217,000 ordinary shares to four non-executive new hires under its 2024 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The options carry an exercise price of $31.57 (closing price on Feb 2, 2026) and vest over four years: 25% after one year, then 36 equal monthly installments, subject to continued service and plan terms.

News Market Reaction – NAMS

+2.04%

1 alert

+2.04% News Effect

On the day this news was published, NAMS gained 2.04%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options granted: 217,000 ordinary shares Number of new hires: 4 non-executive employees Option exercise price: $31.57 per share +5 more

8 metrics

Inducement options granted 217,000 ordinary shares Aggregate options for four non-executive new hires under 2024 Inducement Plan

Number of new hires 4 non-executive employees Recipients of inducement option grants

Option exercise price $31.57 per share Closing Nasdaq price on February 2, 2026 (grant date)

Vesting term 4 years Inducement options vest over four years, service-based

Initial cliff vesting 25% after 1 year First tranche vests on one-year anniversary of vesting commencement

Remaining vesting schedule 36 equal monthly installments After initial 25% cliff, subject to continued service

Share price $32.06 Pre-news price, down 2.79% over prior 24 hours

Market capitalization $3,739,628,716 Equity value prior to this inducement grant disclosure

Market Reality Check

Price: $31.01 Vol: Volume 1,382,582 is 2.03x...

high vol

$31.01 Last Close

Volume Volume 1,382,582 is 2.03x the 20-day average of 680,423, indicating elevated trading activity ahead of this routine grant announcement. high

Technical Shares at $32.06 are trading above the 200-day MA of $27.79 but sit 23.67% below the 52-week high of $42.00 and 128.02% above the 52-week low of $14.06.

Peers on Argus

NAMS fell 2.79% while key biotech peers also traded lower: VKTX -6.47%, MLYS -8....

NAMS fell 2.79% while key biotech peers also traded lower: VKTX -6.47%, MLYS -8.35%, CRNX -5.55%, RARE -3.25%, and APLS -3.22%, suggesting a broader group pullback alongside this company-specific compensation news.

Historical Context

5 past events · Latest: Feb 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	Investor conference	Neutral	-0.0%	Announcement of participation in Guggenheim Emerging Outlook biotech summit.
Jan 09	Strategic update	Positive	-4.0%	Highlights of 2025 achievements, cash of ~$729M, and 2026 priorities.
Jan 05	Inducement grants	Neutral	+1.6%	Inducement options for a new hire under 2024 Inducement Plan.
Dec 05	Inducement grants	Neutral	+1.4%	Inducement options for two non‑executive hires under 2024 plan.
Nov 25	Investor conferences	Neutral	+2.9%	Planned participation in three December 2025 healthcare conferences.

Pattern Detected

Routine corporate and investor-relations updates, including prior inducement grants, have generally seen modest share reactions, with one notable divergence on a positive strategic update.

Recent Company History

Recent news for NewAmsterdam has centered on corporate visibility and routine equity compensation. On Dec 5, 2025 and Jan 5, 2026, the company disclosed similar inducement option grants under the 2024 Inducement Plan, both followed by modest positive price moves. Investor conference participation in Dec 2025 and the Feb 11, 2026 Guggenheim summit also produced limited but generally positive reactions. A Jan 9, 2026 update highlighting 2025 achievements and 2026 priorities, including an expected EMA decision and cash of about $729M, was followed by a negative price move, indicating occasional divergence on constructive strategic updates.

Market Pulse Summary

This announcement details inducement option grants covering 217,000 ordinary shares at an exercise p...

Analysis

This announcement details inducement option grants covering 217,000 ordinary shares at an exercise price of $31.57 for four non‑executive hires under the 2024 Inducement Plan, vesting over four years. It follows a series of similar grants and investor‑relations updates where price reactions were generally modest, with one divergence after a positive strategic update highlighting about $729M in cash. Investors may watch ongoing equity compensation trends, insider Form 4 activity, and upcoming regulatory or clinical milestones when assessing dilution and execution risk.

Key Terms

nasdaq listing rule 5635(c)(4), non-statin, low-density lipoprotein cholesterol, ldl-c, +1 more

5 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-statin medical

"developing oral, non-statin medicines for patients at risk of cardiovascular"

Non-statin describes medicines or treatments used to lower cholesterol or reduce cardiovascular risk that are not part of the statin drug class. Think of statins as the default wrench for a common plumbing problem; non-statins are alternative tools investors watch when statins don’t work, cause side effects, or need to be combined for better results. They matter because approvals, pricing, and adoption of these alternatives can change sales prospects, market share, and long-term demand in cardiovascular care.

low-density lipoprotein cholesterol medical

"with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom"

A form of cholesterol carried in the blood that tends to deposit fatty material on artery walls, often called “bad” cholesterol; think of LDL as delivery trucks that sometimes drop sticky cargo along the body’s highways. Investors monitor LDL because drugs, medical devices, and diagnostic tests that change LDL levels or how they’re managed can drive healthcare spending, regulatory approvals, and company earnings, affecting valuations and risk in health-related businesses.

ldl-c medical

"with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

cardiovascular disease medical

"medicines for patients at risk of cardiovascular disease (“CVD”) with"

A group of conditions that affect the heart and blood vessels, such as heart attacks, strokes and clogged arteries. Think of the cardiovascular system as a body’s plumbing and engine: when pipes narrow or the pump fails, treatment, devices and long-term care become necessary. Investors watch these diseases because their prevalence drives demand for drugs, devices and services, influences healthcare costs and insurer payouts, and affects workforce productivity and regulatory risk.

AI-generated analysis. Not financial advice.

NAARDEN, The Netherlands and MIAMI, Feb. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 217,000 of NewAmsterdam’s ordinary shares to four (4) non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price per share equal to $31.57, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on February 2, 2026, the grant date. The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.

About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com

FAQ

What did NewAmsterdam (NAMS) announce about inducement option grants on February 6, 2026?

They granted inducement options covering 217,000 ordinary shares to four non-executive hires. According to the company, the grants were made under the 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

What is the exercise price and grant date for the NAMS inducement options?

The exercise price is $31.57 per share, reflecting the closing Nasdaq price on Feb 2, 2026. According to the company, that closing price was used to set the exercise price for the grant date.

How do the NAMS inducement options vest for the new hires?

Options vest over four years: 25% at one year, then 36 equal monthly installments thereafter. According to the company, vesting is conditioned on each employee's continued service through the vesting dates.

Under which plan and Nasdaq rule were the NewAmsterdam (NAMS) inducement options granted?

The grants were made under the 2024 Inducement Plan and pursuant to Nasdaq Listing Rule 5635(c)(4). According to the company, this rule permits inducement awards for new employees outside existing equity plans.

How many employees received inducement option grants from NewAmsterdam (NAMS)?

Four non-executive new hires received option grants covering an aggregate of 217,000 shares. According to the company, the awards were material to those employees' acceptance of employment.